LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Aperta

SettoreSettore sanitario

28.48 -2.77

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.4

Massimo

29.34

Metriche Chiave
By Trading Economics
Entrata	-200M -314M
Vendite	428K 2M
Margine di Profitto	-15,692.896
Dipendenti	750
EBITDA	-132M -290M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+20.55% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	5.5B 21B
Apertura precedente	31.25
Chiusura precedente	28.48

Notizie sul Sentiment di mercato

By Acuity

67%

33%

291 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

11 / 11.18 Supporto e resistenza

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 mag 2026, 23:53 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mag 2026, 22:47 UTC

Azioni calde

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mag 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mag 2026, 22:00 UTC

I principali Market Mover

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mag 2026, 18:09 UTC

I principali Market Mover

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mag 2026, 23:50 UTC

Discorsi di Mercato

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mag 2026, 23:36 UTC

Discorsi di Mercato

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mag 2026, 23:07 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 mag 2026, 23:05 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mag 2026, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mag 2026, 15:26 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mag 2026, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mag 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mag 2026, 21:16 UTC

Discorsi di Mercato

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 20:19 UTC

Azioni calde

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mag 2026, 19:41 UTC

Acquisizioni, Fusioni, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mag 2026, 19:35 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mag 2026, 18:35 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

20.55% in crescita

Previsioni per 12 mesi

Media 35.31 USD 20.55%

Alto 41 USD

Basso 29.5 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

11 / 11.18Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

291 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.